Intravenous Immune Globulin Therapy in Dermatomyositis
Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma differentiation-associated gene 5 (anti–MDA-5), nuclear matrix protein 2 (anti–NXP-2), and small ubiquitin-like modifier–activating enzy...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2022-10, Vol.387 (14), p.1320-1321 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1321 |
|---|---|
| container_issue | 14 |
| container_start_page | 1320 |
| container_title | The New England journal of medicine |
| container_volume | 387 |
| creator | Amato, Anthony A. |
| description | Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma differentiation-associated gene 5 (anti–MDA-5), nuclear matrix protein 2 (anti–NXP-2), and small ubiquitin-like modifier–activating enzyme (anti-SAE). Each of these antibodies is referred to by neurologists and rheumatologists by its acronym for convenience,
1
and each is associated with distinct clinical and histopathological features.
2
More than 30 years ago, dermatomyositis was thought to be caused by complement-mediated microangiopathy, but there is evidence that the microvasculopathy and skin and muscle damage associated with dermatomyositis are due primarily to toxicity from pathways mediated by type I . . . |
| doi_str_mv | 10.1056/NEJMe2209117 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2722312524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2722312524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c255t-3d895b6fba6ac89e3a2494e81ed09901f80bf782c22ce67d7705265dfd211acd3</originalsourceid><addsrcrecordid>eNpt0LFOwzAQBmALgUQpbDxAJBgYCNgX24lHBKUUFVjKbDnJRaSKnWInSH17XJUBIW65Gz6dfv2EnDN6w6iQt6-z5xcEoIqx_IBMmMiylHMqD8mEUihSnqvsmJyEsKZxGFcTIhdu8OYLXT-GZGHt6DCZd305dq1LVh_ozWabxPMBvTVDb7d9aIc2nJKjxnQBz372lLw_zlb3T-nybb64v1umFQgxpFldKFHKpjTSVIXCzABXHAuGNVWKsqagZZMXUAFUKPM6z6kAKeqmBsZMVWdTcrX_u_H954hh0LYNFXadcRgTa8gBMgYCeKQXf-i6H72L6XaKyUJwYFFd71Xl-xA8NnrjW2v8VjOqdyXq3yVGfrnn1gbtcG3_Z9_YQW4G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2721685421</pqid></control><display><type>article</type><title>Intravenous Immune Globulin Therapy in Dermatomyositis</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Amato, Anthony A.</creator><creatorcontrib>Amato, Anthony A.</creatorcontrib><description>Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma differentiation-associated gene 5 (anti–MDA-5), nuclear matrix protein 2 (anti–NXP-2), and small ubiquitin-like modifier–activating enzyme (anti-SAE). Each of these antibodies is referred to by neurologists and rheumatologists by its acronym for convenience,
1
and each is associated with distinct clinical and histopathological features.
2
More than 30 years ago, dermatomyositis was thought to be caused by complement-mediated microangiopathy, but there is evidence that the microvasculopathy and skin and muscle damage associated with dermatomyositis are due primarily to toxicity from pathways mediated by type I . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe2209117</identifier><language>eng</language><publisher>Boston: Massachusetts Medical Society</publisher><subject>Allergy ; Antibodies ; Autoimmune Disease ; Autoimmune diseases ; Complement system ; Dermatomyositis ; FDA approval ; Globulins ; Hematology ; Immunoglobulins ; Immunology ; Immunology General ; Immunosuppressive agents ; Inflammatory Disease ; Intravenous administration ; Matrix protein ; Melanoma ; Neurology ; Neuromuscular Disease ; Neurosurgery ; Oncology ; Oncology General ; Rheumatology ; Rheumatology General ; Toxicity ; Ubiquitin</subject><ispartof>The New England journal of medicine, 2022-10, Vol.387 (14), p.1320-1321</ispartof><rights>Copyright © 2022 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c255t-3d895b6fba6ac89e3a2494e81ed09901f80bf782c22ce67d7705265dfd211acd3</citedby><cites>FETCH-LOGICAL-c255t-3d895b6fba6ac89e3a2494e81ed09901f80bf782c22ce67d7705265dfd211acd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe2209117$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2721685421?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52360,54042,64361,64363,64365,72215</link.rule.ids></links><search><creatorcontrib>Amato, Anthony A.</creatorcontrib><title>Intravenous Immune Globulin Therapy in Dermatomyositis</title><title>The New England journal of medicine</title><description>Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma differentiation-associated gene 5 (anti–MDA-5), nuclear matrix protein 2 (anti–NXP-2), and small ubiquitin-like modifier–activating enzyme (anti-SAE). Each of these antibodies is referred to by neurologists and rheumatologists by its acronym for convenience,
1
and each is associated with distinct clinical and histopathological features.
2
More than 30 years ago, dermatomyositis was thought to be caused by complement-mediated microangiopathy, but there is evidence that the microvasculopathy and skin and muscle damage associated with dermatomyositis are due primarily to toxicity from pathways mediated by type I . . .</description><subject>Allergy</subject><subject>Antibodies</subject><subject>Autoimmune Disease</subject><subject>Autoimmune diseases</subject><subject>Complement system</subject><subject>Dermatomyositis</subject><subject>FDA approval</subject><subject>Globulins</subject><subject>Hematology</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Immunology General</subject><subject>Immunosuppressive agents</subject><subject>Inflammatory Disease</subject><subject>Intravenous administration</subject><subject>Matrix protein</subject><subject>Melanoma</subject><subject>Neurology</subject><subject>Neuromuscular Disease</subject><subject>Neurosurgery</subject><subject>Oncology</subject><subject>Oncology General</subject><subject>Rheumatology</subject><subject>Rheumatology General</subject><subject>Toxicity</subject><subject>Ubiquitin</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0LFOwzAQBmALgUQpbDxAJBgYCNgX24lHBKUUFVjKbDnJRaSKnWInSH17XJUBIW65Gz6dfv2EnDN6w6iQt6-z5xcEoIqx_IBMmMiylHMqD8mEUihSnqvsmJyEsKZxGFcTIhdu8OYLXT-GZGHt6DCZd305dq1LVh_ozWabxPMBvTVDb7d9aIc2nJKjxnQBz372lLw_zlb3T-nybb64v1umFQgxpFldKFHKpjTSVIXCzABXHAuGNVWKsqagZZMXUAFUKPM6z6kAKeqmBsZMVWdTcrX_u_H954hh0LYNFXadcRgTa8gBMgYCeKQXf-i6H72L6XaKyUJwYFFd71Xl-xA8NnrjW2v8VjOqdyXq3yVGfrnn1gbtcG3_Z9_YQW4G</recordid><startdate>20221006</startdate><enddate>20221006</enddate><creator>Amato, Anthony A.</creator><general>Massachusetts Medical Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20221006</creationdate><title>Intravenous Immune Globulin Therapy in Dermatomyositis</title><author>Amato, Anthony A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c255t-3d895b6fba6ac89e3a2494e81ed09901f80bf782c22ce67d7705265dfd211acd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Allergy</topic><topic>Antibodies</topic><topic>Autoimmune Disease</topic><topic>Autoimmune diseases</topic><topic>Complement system</topic><topic>Dermatomyositis</topic><topic>FDA approval</topic><topic>Globulins</topic><topic>Hematology</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Immunology General</topic><topic>Immunosuppressive agents</topic><topic>Inflammatory Disease</topic><topic>Intravenous administration</topic><topic>Matrix protein</topic><topic>Melanoma</topic><topic>Neurology</topic><topic>Neuromuscular Disease</topic><topic>Neurosurgery</topic><topic>Oncology</topic><topic>Oncology General</topic><topic>Rheumatology</topic><topic>Rheumatology General</topic><topic>Toxicity</topic><topic>Ubiquitin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amato, Anthony A.</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amato, Anthony A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous Immune Globulin Therapy in Dermatomyositis</atitle><jtitle>The New England journal of medicine</jtitle><date>2022-10-06</date><risdate>2022</risdate><volume>387</volume><issue>14</issue><spage>1320</spage><epage>1321</epage><pages>1320-1321</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Dermatomyositis is a heterogeneous syndrome with several associated antibodies, such as those against transcription intermediary factor 1-γ (anti–TIF-1γ), melanoma differentiation-associated gene 5 (anti–MDA-5), nuclear matrix protein 2 (anti–NXP-2), and small ubiquitin-like modifier–activating enzyme (anti-SAE). Each of these antibodies is referred to by neurologists and rheumatologists by its acronym for convenience,
1
and each is associated with distinct clinical and histopathological features.
2
More than 30 years ago, dermatomyositis was thought to be caused by complement-mediated microangiopathy, but there is evidence that the microvasculopathy and skin and muscle damage associated with dermatomyositis are due primarily to toxicity from pathways mediated by type I . . .</abstract><cop>Boston</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJMe2209117</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2022-10, Vol.387 (14), p.1320-1321 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2722312524 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Allergy Antibodies Autoimmune Disease Autoimmune diseases Complement system Dermatomyositis FDA approval Globulins Hematology Immunoglobulins Immunology Immunology General Immunosuppressive agents Inflammatory Disease Intravenous administration Matrix protein Melanoma Neurology Neuromuscular Disease Neurosurgery Oncology Oncology General Rheumatology Rheumatology General Toxicity Ubiquitin |
| title | Intravenous Immune Globulin Therapy in Dermatomyositis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T02%3A34%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20Immune%20Globulin%20Therapy%20in%20Dermatomyositis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Amato,%20Anthony%20A.&rft.date=2022-10-06&rft.volume=387&rft.issue=14&rft.spage=1320&rft.epage=1321&rft.pages=1320-1321&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe2209117&rft_dat=%3Cproquest_cross%3E2722312524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2721685421&rft_id=info:pmid/&rfr_iscdi=true |